179 related articles for article (PubMed ID: 36799104)
1. Functional Analysis of CXCR3 Splicing Variants and Their Ligands Using NanoBiT-Based Molecular Interaction Assays.
Nguyen HT; Hurh S; Nguyen LP; Nguyen TU; Park HK; Seong JY; Lee CS; Ham BJ; Hwang JI
Mol Cells; 2023 May; 46(5):281-297. PubMed ID: 36799104
[TBL] [Abstract][Full Text] [Related]
2. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.
Manousou P; Kolios G; Drygiannakis I; Koulentaki M; Pyrovolaki K; Voumvouraki A; Notas G; Bourikas L; Papadaki HA; Kouroumalis E
Clin Exp Immunol; 2013 Apr; 172(1):9-15. PubMed ID: 23480180
[TBL] [Abstract][Full Text] [Related]
3. CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.
Berchiche YA; Sakmar TP
Mol Pharmacol; 2016 Oct; 90(4):483-95. PubMed ID: 27512119
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha2b restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by modulating CXC receptor ligand interaction.
Chakraborty K; Bose A; Pal S; Chattopadhyay U; Baral R
J Interferon Cytokine Res; 2008 Aug; 28(8):487-99. PubMed ID: 18729739
[TBL] [Abstract][Full Text] [Related]
5. C-X-C Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways.
Smith JS; Alagesan P; Desai NK; Pack TF; Wu JH; Inoue A; Freedman NJ; Rajagopal S
Mol Pharmacol; 2017 Aug; 92(2):136-150. PubMed ID: 28559424
[TBL] [Abstract][Full Text] [Related]
6. Disparate roles of CXCR3A and CXCR3B in regulating progressive properties of colorectal cancer cells.
Li H; Rong S; Chen C; Fan Y; Chen T; Wang Y; Chen D; Yang C; Yang J
Mol Carcinog; 2019 Feb; 58(2):171-184. PubMed ID: 30302818
[TBL] [Abstract][Full Text] [Related]
7. CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma.
Jinquan T; Quan S; Jacobi HH; Jing C; Millner A; Jensen B; Madsen HO; Ryder LP; Svejgaard A; Malling HJ; Skov PS; Poulsen LK
Blood; 2000 Aug; 96(4):1230-8. PubMed ID: 10942362
[TBL] [Abstract][Full Text] [Related]
8. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion.
Wu Q; Dhir R; Wells A
Mol Cancer; 2012 Jan; 11():3. PubMed ID: 22236567
[TBL] [Abstract][Full Text] [Related]
9. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.
Proost P; Schutyser E; Menten P; Struyf S; Wuyts A; Opdenakker G; Detheux M; Parmentier M; Durinx C; Lambeir AM; Neyts J; Liekens S; Maudgal PC; Billiau A; Van Damme J
Blood; 2001 Dec; 98(13):3554-61. PubMed ID: 11739156
[TBL] [Abstract][Full Text] [Related]
10. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
[TBL] [Abstract][Full Text] [Related]
11. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.
Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE
Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630
[TBL] [Abstract][Full Text] [Related]
12. Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis.
Furuya M; Yoneyama T; Miyagi E; Tanaka R; Nagahama K; Miyagi Y; Nagashima Y; Hirahara F; Inayama Y; Aoki I
Gynecol Oncol; 2011 Sep; 122(3):648-55. PubMed ID: 21684584
[TBL] [Abstract][Full Text] [Related]
13. CXCR3A contributes to the invasion and metastasis of gastric cancer cells.
Yang C; Zheng W; Du W
Oncol Rep; 2016 Sep; 36(3):1686-92. PubMed ID: 27461521
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of pericyte function by the CXC receptor 3.
Bodnar RJ; Wells A
Wound Repair Regen; 2015; 23(6):785-96. PubMed ID: 26207932
[TBL] [Abstract][Full Text] [Related]
15. CXCR3 expression on CD34(+) hemopoietic progenitors induced by granulocyte-macrophage colony-stimulating factor: II. Signaling pathways involved.
Jinquan T; Anting L; Jacobi HH; Glue C; Jing C; Ryder LP; Madsen HO; Svejgaard A; Skov PS; Malling HJ; Poulsen LK
J Immunol; 2001 Oct; 167(8):4405-13. PubMed ID: 11591765
[TBL] [Abstract][Full Text] [Related]
16. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states.
Cox MA; Jenh CH; Gonsiorek W; Fine J; Narula SK; Zavodny PJ; Hipkin RW
Mol Pharmacol; 2001 Apr; 59(4):707-15. PubMed ID: 11259614
[TBL] [Abstract][Full Text] [Related]
17. CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma.
Jinquan T; Jing C; Jacobi HH; Reimert CM; Millner A; Quan S; Hansen JB; Dissing S; Malling HJ; Skov PS; Poulsen LK
J Immunol; 2000 Aug; 165(3):1548-56. PubMed ID: 10903763
[TBL] [Abstract][Full Text] [Related]
18. CXCR3 ligands in disease and therapy.
Van Raemdonck K; Van den Steen PE; Liekens S; Van Damme J; Struyf S
Cytokine Growth Factor Rev; 2015 Jun; 26(3):311-27. PubMed ID: 25498524
[TBL] [Abstract][Full Text] [Related]
19. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis.
Colvin RA; Campanella GS; Manice LA; Luster AD
Mol Cell Biol; 2006 Aug; 26(15):5838-49. PubMed ID: 16847335
[TBL] [Abstract][Full Text] [Related]
20. Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands.
McColl SR; Mahalingam S; Staykova M; Tylaska LA; Fisher KE; Strick CA; Gladue RP; Neote KS; Willenborg DO
Lab Invest; 2004 Nov; 84(11):1418-29. PubMed ID: 15322564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
